...
首页> 外文期刊>Mediators of inflammation >Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients
【24h】

Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients

机译:磷酸二酯酶4D型基因多态性:与小儿哮喘患者对短效支气管扩张药的反应相关

获取原文
           

摘要

Short-acting b2-adrenergic receptor agonists are commonly used bronchodilators for symptom relief in asthmatics. The aim of this study was to test whether genetic variants inPDE4Dgene, a key regulator of b2-adrenoceptor-induced cAMP turnover in airway smooth muscle cells, affect the response to short-acting b2-agonists. Bronchodilator responsiveness was assessed in 133 asthmatic children by % change in baseline forced expiratory volume in one second (FEV1) after administration of albuterol. The analyses were performed in patients with airway obstruction (FEV1/FVC ratio below 90%,n=93). FEV1  % change adjusted for baseline FEV1values was significantly different between genotypes of rs1544791 G/A polymorphism (P=0.006) and −1345 C/T (rs1504982) promoter variation (P=0.03). The association remained significant with inclusion of age, sex, atopy, and controller medication into multivariate model (P=0.004andP=0.02, resp.). Our work identifies new genetic variants implicated in modulation of asthma treatment, one of them (rs1544791) previously associated with asthma phenotype.
机译:短效b2-肾上腺素能受体激动剂是哮喘患者缓解症状时常用的支气管扩张药。这项研究的目的是测试气道平滑肌细胞中bDE受体介导的cAMP转换的关键调节因子PDE4Dgene中的遗传变异是否影响对短效b2-激动剂的反应。通过在服用沙丁胺醇后一秒钟内基线强迫呼气量(FEV1)的百分比变化来评估133名哮喘儿童的支气管扩张药反应性。对气道阻塞(FEV1 / FVC比率低于90%,n = 93)的患者进行分析。 rs1544791 G / A多态性(P = 0.006)和-1345 C / T(rs1504982)启动子变异的基因型之间,针对基线FEV1值调整的FEV1%变化显着不同。在将年龄,性别,特应性疾病和控制药物纳入多变量模型后,这种关联仍然很显着(分别为P = 0.004和P = 0.02)。我们的工作确定了与哮喘治疗的调节有关的新遗传变异,其中之一(rs1544791)以前与哮喘表型有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号